Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1104)	11/12/2001 9:25:56 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

part 3 by: soldier30 11/12/01 08:53 pm Msg: 1294 of 1302 Phase III trials. Importantly, we anticipate MedImmune could complete these Phase II trials during 2001 and initiate MEDI-507 Phase III psoriasis trials during 1Q 2002. We expect positive Phase II MEDI-507 clinical results to act as a catalyst for BTRN shares. We believe, based on the clinical development schedule for MEDI-507, MEDI-507 is approximately 8-12 months behind Amevive and Xanelim. We also believe MedImmune could benefit from MEDI-507 trailing both Amevive and Xanelim to the market as this timing could allow MedImmune to design a Phase III program for MEDI-507 that would permit MedImmune to differentiate the product in the market. We anticipate duration of effect combined with a product's efficacy, dosing schedule and side effect profile will be important parameters that differentiate psoriasis products. Strong preliminary AlloMune and T-CellHDM System data to be presented at the American Society of Hematology (ASH) annual Meeting. Earlier this week, abstracts for the upcoming ASH meeting to be held in Orlando, Florida on December 7-11, 2001 became available on-line. BioTransplant has three abstracts scheduled for presentation at the conference. Specifically, BioTransplant's TCell-HDM system is highlighted in one abstract titled "A Randomized Trial of CD8+ T Cell Depletion To Prevent Graft-Vs-Host Disease (GVHD) Associated with Donor Lymphocyte Infusions", and BioTransplant's Allomune process is featured in two other abstracts titled "Durable Progression Free Survival (PFS) Following Non-Myeloablative Bone Marrow Transplantation (BMT) for Chemorefractory Diffuse Large B Cell Lymphoma (B-LCL)" and "Achievement of Sustained Remissions Despite Loss of Donor Chimerism (DC) in Patients with Chemotherapy-Refractory Non-Hodgkin's Lymphoma (NHL) Treated with Nonmyeloablative Conditioning and Allogeneic Stem Cell Transplantation (SCT)." (Please see abstracts 3554, 2813 and 1753 attached below.)